Abstract: A method for preparing an ultrathin Li complex includes the steps of preparing an organic transition layer on a substrate in advance, and contacting the substrate having transition layer with molten Li in argon atmosphere with H2O?0.1 ppm and O2?0.1 ppm. The molten Li spreads rapidly on the surface of the substrate to form a lithium thin layer. The ultrathin Li layer stores lithium on the current collector beforehand. It can be used as a safe lithium anode to inhibit dendrites.

Abstract: A method for separating a metallofullerene M@C82, comprises steps of: a) adding a Lewis acid to an extract containing the metallofullerene M@C82 to react therewith, producing a complex precipitate; b) washing the precipitate, followed by dissolving and filtering to obtain a purified metallofullerene M@C82 extract, wherein M is one or more selected from the group consisting of lanthanide metals Ce, Pr, Nd, Sm, Eu, Gd, Tb, Dy, Ho, Er, Yb, and Lu; and the Lewis acid is one or more selected from the group consisting of zinc chloride, nickel chloride, copper chloride, zinc bromide, nickel bromide, and copper bromide.

Abstract: A method for preparing an ultrathin Li complex includes the steps of preparing an organic transition layer on a substrate in advance, and contacting the substrate having transition layer with molten Li in argon atmosphere with H2O?0.1 ppm and O2?0.1 ppm. The molten Li spreads rapidly on the surface of the substrate to form a lithium thin layer. The ultrathin Li layer stores lithium on the current collector beforehand. It can be used as a safe lithium anode to inhibit dendrites.

Abstract: An application of a fullerene structure in the preparation of medications for treating Parkinson's disease. The fullerene structure comprises at least one of the following active ingredient groups: a fullerene, a metallofullerene, and a composition of the fullerene and the metallofullerene; an oil-soluble fullerene, an oil-soluble metallofullerene, and a composition of the oil-soluble fullerene and the oil-soluble metallofullerene; a water-soluble fullerene, a water-soluble metallofullerene, and a composition of the water-soluble fullerene and the water-soluble metal-lofullerene; the medicinal esters of the nine elements, or the medicinal salts of the nine elements.

Abstract: An application of a fullerene structure in the preparation of medications for treating Parkinson's disease. The fullerene structure comprises at least one of the following active ingredient groups: a fullerene, a metallofullerene, and a composition of the fullerene and the metallofullerene; an oil-soluble fullerene, an oil-soluble metallofullerene, and a composition of the oil-soluble fullerene and the oil-soluble metallofullerene; a water-soluble fullerene, a water-soluble metallofullerene, and a composition of the water-soluble fullerene and the water-soluble metallofullerene; the medicinal esters of the nine elements, or the medicinal salts of the nine elements.

Abstract: Metallofullerene monocrystalline nanoparticles are used as tumor vascular disrupting agents. The monocrystalline nanoparticles are water-soluble metallofullerene nanoparticles with negative charges on their surfaces. The particle sizes range from 50 to 250 nanometers. The nanomaterials are able to absorb outside radiation energy, and transform it into heat energy. The volumes rapidly expand when temperature reaches a phase transformation point. For treatment, metallofullerene monocrystalline nanoparticles are administrated to a tumor-bearing organism via injection. The metallofullerene monocrystalline nanoparticles reach tumor sites via blood circulation, and are retained at the tumor sites. The monocrystalline nanoparticles of metallofullerene accumulate heat and the temperature increases under outside radiation energy.

Abstract: A method for separating a metallofullerene M@C82, comprises steps of: a) adding a Lewis acid to an extract containing the metallofullerene M@C82 to react therewith, producing a complex precipitate; b) washing the precipitate, followed by dissolving and filtering to obtain a purified metallofullerene M@C82 extract, wherein M is one or more selected from the group consisting of lanthanide metals Ce, Pr, Nd, Sm, Eu, Gd, Tb, Dy, Ho, Er, Yb, and Lu; and the Lewis acid is one or more selected from the group consisting of zinc chloride, nickel chloride, copper chloride, zinc bromide, nickel bromide, and copper bromide.

Abstract: Provided is an application of a fullerene/metal-fullerene micro/nanomaterial for preparing a pharmaceutical product. The pharmaceutical product has at least one of the following properties: 1) treats a bone marrow suppression; 2) treats at least one of the following conditions caused by the bone marrow suppression: white blood cell count reduction, platelet count reduction, hemo-globin count reduction, and monocyte count reduction; 3) protects a bone marrow cell and/or a hematopoietic cell; 4) able to build up in a bone marrow; 5)protects the liver, spleen, and kidneys; 6) removes a free radical; and 7) improves the performance of an antioxidant system in an organism.

Abstract: An application of a fullerene structure in the preparation of medications for treating Parkinson's disease. The fullerene structure comprises at least one of the following active ingredient groups: a fullerene, a metallofullerene, and a composition of the fullerene and the metallofullerene; an oil-soluble fullerene, an oil-soluble metallofullerene, and a composition of the oil-soluble fullerene and the oil-soluble metallofullerene; a water-soluble fullerene, a water-soluble metallofullerene, and a composition of the water-soluble fullerene and the water-soluble metal-lofullerene; the medicinal esters of the nine elements, or the medicinal salts of the nine elements.

Abstract: Metallofullerene monocrystalline nanoparticles are used as tumor vascular disrupting agents. The monocrystalline nanoparticles are water-soluble metallofullerene nanoparticles with negative charges on their surfaces. The particle sizes range from 50 to 250 nanometers. The nanomaterials are able to absorb outside radiation energy, and transform it into heat energy. The volumes rapidly expand when temperature reaches a phase transformation point. For treatment, metallofullerene monocrystalline nanoparticles are administrated to a tumor-bearing organism via injection. The metallofullerene monocrystalline nanoparticles reach tumor sites via blood circulation, and are retained at the tumor sites. The monocrystalline nanoparticles of metallofullerene accumulate heat and the temperature increases under outside radiation energy.